e-ISSN: Pending
Replication FailureOpen accessMedicine· cited by 9

Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients

Christopher C. Butler; Andrew Pinto; Victoria Harris; Jane Holmes; Najib M. Rahman; Lucy Cureton; Gail Hayward; Duncan B. Richards · 2026 · New England Journal of Medicine

WASTE classifies this as Replication Failure · AI classification, approximate

A previously reported effect did not replicate here — verify it holds before you build on it.

Abstract

BACKGROUND: Nirmatrelvir-ritonavir has been shown to reduce progression to severe illness from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in unvaccinated high-risk outpatients. The effectiveness of nirmatrelvir-ritonavir in persons who have been vaccinated, infected naturally, or both is unclear. METHODS: In two open-label platform trials (PANORAMIC in the United Kingdom and CanTreatCOVID in Canada), we enrolled higher-risk adults (≥50 years of age or ≥18 years of age with coexisting conditions) in the community who tested positive for SARS-CoV-2 and had been unwell for 5 day

Abstract by Christopher C. Butler; Andrew Pinto; Victoria Harris; Jane Holmes; Najib M. Rahman; Lucy Cureton; Gail Hayward; Duncan B. Richards, New England Journal of Medicine (2026) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1056/nejmoa2502457